KR-20260066139-A - Nasal composition for the prevention and/or treatment of viral and bacterial infections

Abstract

The present invention relates to the field of medicine, more particularly to pharmacology, and can be used for the prevention and/or treatment of viral and bacterial infections of the nasopharynx and nasal cavity, including coronavirus infections, influenza, and other acute respiratory viral infections. An intranasal composition for the prevention and/or treatment of inflammatory infectious diseases of the nasal cavity comprises high molecular weight hyaluronic acid, high molecular weight polyvinylpyrrolidone (high molecular weight PVP), poviargol, antibacterial polypeptide, sodium hypochlorite solution, and gelofuzin, said components present in given proportions.

Inventors

• 아피노게노프, 겐나디 예브게니예비치
• 아피노게노바, 안나 겐나디예브나
• 마텔로, 스베틀라나 콘스탄티노브나
• 마나셰로프, 타마즈 오마로비치
• 암브로소프, 이고르 발레리예비치

Assignees

• 오브셰스트보 스 오그라니첸노이 오트베트스트벤노스티유 ≪더블유디에스≫

Dates

Publication Date

20260512

Application Date

20240925

Priority Date

20230926

Claims (12)

1. An intranasal composition for the prevention and/or treatment of infectious and inflammatory diseases of the nasal cavity, comprising high molecular weight hyaluronic acid, high molecular weight polyvinylpyrrolidone (high molecular weight PVP), poviagol, antibacterial polypeptide, sodium hypochlorite solution, and gelofuzin, having the following component ratios in weight%: High molecular weight hyaluronic acid - 0.1-2.0; High molecular weight PVP - 4.0-6.0; Pobiargol - 0.8-1.2; Antibacterial polypeptide - 0.03-18.0; Sodium hypochlorite solution - 49.0-51.0; Gelofuzin - Amount to reach 100.0.
2. A composition according to claim 1, characterized in that the amount of high molecular weight hyaluronic acid is 0.5-2 weight%.
3. A composition according to claim 1, characterized in that the amount of high molecular weight hyaluronic acid is 1-2 weight%.
4. A composition according to claim 1, characterized in that the amount of high molecular weight PVP is 4.5-5.5 weight%.
5. A composition according to claim 1, characterized in that the amount of poviargol is 0.8-1 weight%.
6. A composition according to claim 1, characterized in that the antibacterial peptide is gramicidin C or lysozyme.
7. A composition according to claim 6, characterized in that the amount of gramicidin C is 0.03-0.15 weight%.
8. A composition according to claim 6, characterized in that the amount of lysozyme is 0.1-18.0 weight%.
9. A composition according to claim 6, characterized in that the amount of lysozyme is 1-16.0 weight%.
10. A composition according to claim 1, characterized in that infectious and inflammatory diseases of the nasal cavity are caused by coronavirus, influenza virus, other RNA- and DNA-containing viruses and bacteria accompanied by the formation of a microbial biofilm.
11. A use of an intranasal composition according to claim 1 for the prevention and/or treatment of infectious and inflammatory diseases of the nasal cavity caused by coronavirus, influenza virus, other RNA- and DNA-containing viruses and bacteria accompanied by the formation of a microbial biofilm, wherein said composition is applied to the nasal mucosa once a day.
12. A use characterized in that, in paragraph 11, the composition is used alone or as part of a combination therapy.

Description

Nasal composition for the prevention and/or treatment of viral and bacterial infections The present invention relates to the field of medicine, namely the field of pharmacology, and can be used for the prevention and/or treatment of viral and bacterial infections of the nasopharynx and nasal cavity, including coronavirus infection, influenza, and other acute respiratory viral infections. The increasing role of infectious viral diseases in the general morbidity patterns of the population and the emergence of new dangerous viruses (including previously unidentified ones) spur the development and implementation of promising antimicrobial compositions with a broad spectrum and sustained action. The nasal cavity is an antimicrobial filter where an extensive airborne microbiome appears, including fungal spores, Bacillus, Micrococcus, non-pathogenic Neisseria, Epidermal Staphylococcus, and Beta-hemolytic Streptococcus. Random nasal residents include Pneumococcus, Klebsiella pneumoniae, Staphylococcus aureus, influenza bacteria, and Candida. These species can cause self-infections—rhinitis, bronchitis, nasopharyngitis, and pneumonia—as well as serve as a source of infection for others. In children, the nasal microbiome is much richer and more diverse. The prototype of the claimed solution is the invention according to patent RU 2616523 C1 (April 17, 2017, IPC A61K9/06, A61K31/22, A61K36/61, A61K36/53, A61P31/04, A61P31/16), which is an intranasal ointment for the treatment and prevention of respiratory infections. According to the description, the invention is characterized by a sustained effect provided by the synergistic effect of the individual components of the drug. The results of drug use have been shown in patients with influenza and acute respiratory viral infections. The authors of this invention have not specified the necessary frequency of use and duration of the intranasal ointment that affect the achievement of the claimed treatment and prevention. In addition, the authors did not confirm the claimed antiviral effect resulting from the synergistic action of the individual components of the ointment with the results of their in vitro studies. The authors also did not provide data on the effect of the intranasal ointment against human coronavirus, influenza virus, and other RNA- and DNA-containing viruses, nor did they claim the antibacterial effect of the ointment or its effect on microbial biofilms. The objective of the present invention is to address the problem of the lack of effective broad-spectrum compositions for the prevention and/or comprehensive treatment of infectious and inflammatory diseases of the nasal cavity when used intranasally. The technical result of the invention is the development of a broad-spectrum composition that is more effective than the prototype for the prevention and/or comprehensive treatment of infectious and inflammatory diseases of the nasal cavity when used intranasally, which has sustained broad-spectrum antimicrobial activity, particularly against human coronavirus, influenza virus, other RNA- and DNA-containing viruses and bacteria, and can prevent the formation of microbial biofilms and destroy already formed microbial biofilms. The problem is solved by developing a composition for application to the nasal cavity and the specified technical results are achieved, the composition is characterized by comprising high molecular weight hyaluronic acid, high molecular weight polyvinylpyrrolidone (PVP), gelofuzine, sodium hypochlorite, poviargol, and an antibacterial polypeptide having the following component ratios in weight percent, wherein the antibacterial polypeptide is gramicidin C or lysozyme: - High molecular weight hyaluronic acid - 0.1-2.0; - High molecular weight PVP - 4.0-6.0; - Pobiargol - 0.8-1.2; - Antibacterial polypeptide (gramicidin C - 0.03-0.15, or lysozyme - 0.1-18.0); - Sodium hypochlorite solution with an active chlorine content of 1566 mg/l - 49.0-51.0; - Gelofugin - Amount to reach 100.0. The quantitative and qualitative combination of components in the composition proposed for the patent application results in the occurrence of a synergistic effect. Another objective of the invention is the use of the claimed composition for the prevention and/or treatment of infectious and inflammatory diseases of the nasal cavity caused by coronavirus, influenza virus, other RNA- and DNA-containing viruses and bacteria accompanied by the formation of microbial film (particularly during periods of exacerbation of seasonal infectious diseases, epidemics and pandemics), characterized by the fact that the composition is applied to the nasal mucosa for preventive or therapeutic purposes once a day. In the context of the present invention, the term “high molecular weight hyaluronic acid” characterizes non-sulfated glycosaminoglycans that are part of connective, epithelial, and neural tissues. High molecular weight hyaluronic acid is one of the major components of th